Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Takeda
University of Illinois at Chicago
Centre Oscar Lambret
Institut Paoli-Calmettes
National Institutes of Health Clinical Center (CC)
University of Chicago
Incyte Corporation
University of Nebraska
Massachusetts General Hospital
M.D. Anderson Cancer Center
Massachusetts General Hospital
Roswell Park Cancer Institute
Gamida Cell ltd
Columbia University
BeOne Medicines
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
University of Kentucky
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Mayo Clinic
University of Rochester
University of Rochester
National Research Center for Hematology, Russia
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
First Affiliated Hospital of Zhejiang University
Children's Hospital Los Angeles
Baylor College of Medicine
National Institutes of Health Clinical Center (CC)
University of Iowa
Thomas Jefferson University
BeOne Medicines
Medical College of Wisconsin
Baylor College of Medicine
Eli Lilly and Company
University of Colorado, Denver
Newave Pharmaceutical Inc
Fred Hutchinson Cancer Center
CHU de Reims
University of Rochester
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Chang Gung University
Massachusetts General Hospital
M.D. Anderson Cancer Center
Brown University